[Monoclonal antibodies in organ transplantation].
Polyclonal anti-lymphoyctes antibodies were first successfully used in the 1970 in organ transplantation, but ten years later, monoclonal antibodies (mAb) emerged as a new class of immunosuppressive agents in transplantation with the potential to target highly specifically immune cells responsible for acute rejection. Some have proved their efficacy, such as mAb recognizing CD3- and CD25-positive T cells and have been extensively studied in clinical trials. Others such as mAb against CD52 and CD20, are still under investigation; finally, the next challenge is, based on our improved understanding of the mechanisms of immune recognition and allograft rejection, to use these mAb either alone or in combination with standard immunosuppressive regimens to manipulate the allogenic response to reach antigen-specific tolerance desired in solid-organ transplantation.
Vanhove
Bernard
B
Inserm U643, Nantes, F44093 France. Bernard.Vanhove@univ-nantes.fr
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000074301:CD52 Antigen; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006023:Glycoproteins / Q000276:immunology; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D000961:Antilymphocyte Serum; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; C508017:IL2RA protein, human; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D016853:Muromonab-CD3